Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Assess Effectiveness and Tolerability of Zavegepant as an Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications.

NCT06401642 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06401642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06401642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Assess Effectiveness and Tolerability of Zavegepant as an Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications.
Lead sponsor
Mayo Clinic
Phase
Phase 4
Overall status
Recruiting
Start date
March 22, 2024
Completion date
March 31, 2027
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

migraine